Drug Trial Radar · NCT04917315
To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder
Last checked: Nov 20, 2026Latest source record: Jan 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
210
Actual
Start
May 21, 2020
Primary completion
Aug 18, 2021
Study completion Aug 18, 2021
Sponsor
- Lead sponsor
- Jeil Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Overactive bladder (OAB) is a clinical condition characterized by urgency (i.e., urinary urinary urinary urgency that is difficult to delay and unbearable) with or without urge incontinence, usually associated with frequency and nocturia. The main drug class used is antimuscarinics, and the clinical utility of antimuscarinic drugs is limited due to its mild efficacy and poor tolerability due to side effects of mechanisms such as dry mouth and constipation. In addition to poor tolerability and mild efficacy, recent literature suggests that long-term use of anticholinergics is associated with cognitive impairment and dementia. Therefore, the purpose of this study was to evaluate the treatment effect of overactive bladder symptoms through the change in the average number of urination per day after administration of JLP-2002, a beta 3-adrenergic receptor (β3-AR) agonist with an effective alternative mechanism, for 12 weeks.
Conditions
- Overactive Bladder
Interventions
JLP-2002 A mgDrug
administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.
PlaceboDrug
administration of Placebo Participants received one placebo tablet, taken orally each morning, for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Average Daily Micturitions at Week 12Time frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.